Healthcare Active Stocks: MannKind Corporation (NASDAQ:MNKD), Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR), Pfizer Inc. (NYSE:PFE), AbbVie Inc (NYSE:ABBV), Gilead Sciences (NASDAQ:GILD)


MannKind Corporation’s (MNKD) search for a partner to market its only approved product Afrezza ended with the company inking a global licensing deal with French company Sanofi (SNY). Afrezza was cleared by the FDA in Jun 2014 for the improvement of glycemic control in adults suffering from diabetes mellitus. Shares of MannKind Corporation (NASDAQ:MNKD) closed at 8.53 in last trading session. Yesterday share price of the company was traded in the range of 8.31 – 10.08. Company now has a market value of 3.31 billion. MannKind Corporation (NASDAQ:MNKD) price to cash ratio past twelve months was calculated as 92.59.

Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR) has made a name for itself pioneering new experimental treatments in the wake of the most recent Ebola scare. Ebola is considered one of the deadliest viruses on the planet with a fatality rate of up to 90%. Tekmira is one of a few companies which are looking to tackle this problem. Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) stock traded in the range of 22.23 – 26.05 and at the end of the day, it closed at 23.80. Average trading volume of the company is 1.49.

Pfizer Inc. (NYSE:PFE) is facing an increasing number of lawsuits related to its anti-cholesterol drug Lipitor from women who accuse the company of deliberately withholding information about side effects pertaining to use of the drug. Pfizer Inc.(NYSE:PFE) after opening at 28.53, moved down -0.32% to 28.25 on last trading day. Company’s 52 week range is27.76 – 32.96.

U.S. drug maker AbbVie Inc. said Friday it reached a deal to buy Shire PLC for about $54 billion, one of the largest deals to date where a U.S. company seeks to lower its tax rate by buying a foreign rival. AbbVie Inc (NYSE:ABBV) stock hit highest price at 53.65, beginning with a price of 53.00 and increased 0.93%to the close at 53.31. With day range of 52.77 – 53.65 The total market capitalization of the stock is 84.89 billion.

The Times of India reported earlier this week that Gilead offered to sell Sovaldi at what amounts to a 99% discount for the impoverished nation, following its plan to sell the highly effective treatment in Egypt at the same $900 price tag. Gilead Sciences, Inc. (NASDAQ:GILD) stock traded in the range of 92.52 – 93.31 and at the end of the day, it closed at 92.92. Average trading volume of the company is 11.18. Gilead Sciences, Inc. (NASDAQ:GILD) return on equity ratio is recorded as 57.30% and its return on assets is 28.60%.


Leave a Reply

Your email address will not be published. Required fields are marked *